Xi Ding

Zhuhai, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.

Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.

Journal: BMJ (Clinical research ed.)
Published: February 10, 2026

Comparison of ≥2 lines immunotherapy regimens for recurrent/metastatic nasopharyngeal carcinoma.

Comparison of ≥2 lines immunotherapy regimens for recurrent/metastatic nasopharyngeal carcinoma.

Journal: International journal of cancer
Published: June 11, 2025

Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal Carcinoma.

Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal Carcinoma.

Journal: NEJM evidence
Published: April 22, 2025

TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: An open-label, single-arm, phase II trial.

TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: An open-label, single-arm, phase II trial.

Journal: Med (New York, N.Y.)
Published: April 17, 2025

Endoscopic Transoropharyngeal Retropharyngeal Lymph Node (RPLN) Dissection for RPLN Recurrence Nasopharyngeal Carcinoma.

Endoscopic Transoropharyngeal Retropharyngeal Lymph Node (RPLN) Dissection for RPLN Recurrence Nasopharyngeal Carcinoma.

Journal: Annals of surgical oncology
Published: January 20, 2025

Radiation-induced rhinosinusitis in patients with nasopharyngeal carcinoma.

Radiation-induced rhinosinusitis in patients with nasopharyngeal carcinoma.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: November 23, 2024

Lachnoclostridium intestinal flora is associated with immunotherapy efficacy in nasopharyngeal carcinoma.

Lachnoclostridium intestinal flora is associated with immunotherapy efficacy in nasopharyngeal carcinoma.

Journal: Head & neck
Published: May 29, 2024

A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma.

A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma.

Journal: Cell reports. Medicine
Published: July 23, 2023

A novel endoscopic nasopharyngectomy by low-temperature plasma radiofrequency ablation in localized recurrent nasopharyngeal carcinoma.

A novel endoscopic nasopharyngectomy by low-temperature plasma radiofrequency ablation in localized recurrent nasopharyngeal carcinoma.

Journal: Head & neck
Published: May 11, 2023

Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial.

Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial.

Journal: Cell reports. Medicine
Published: March 17, 2023

Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study.

Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study.

Journal: EClinicalMedicine
Published: March 06, 2023

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 03, 2023
Showing 1-12 of 17

Last Updated: 09/26/2026